Piper Jaffray analyst William Quirk lowered his price target for Pacific Biosciences (PACB) to $6 from $10 after Roche (RHHBY) terminated its Sequel system contract with the company. Pacific Biosciences believes Roche's decision stems from a change in the sequencing market dynamics, the analyst notes, adding that Roche said "somewhat vaguely" that Sequel can no longer meet a list of requirements the company established. Additionally, Quirk believes the mid-point of Pacific Biosciences' 2017 guidance may be difficult to reach, and reiterates a Neutral rating on the shares.